including begin Thanks, Carrie, progress, and customer call exciting today our this will providing thank joining by on I for you, recent some everyone, data. afternoon. updates our us
in grew the and cash XXXX I turn biological equivalents call million into investments. I financial share taking results to over will Looking David, XXXX, this to were for provide year and $XX.X million ahead, ended focused And more will detail to X%, adoption. XXXX.
In the we accelerated the commercial for $XXX these then are to converting revenue happen. with and insights laser over cash, revenue outlook on actions the incredible make our on we
adoption biological expectations. and I of aligned and revenue will data insights more expect with our grows, become the As body
researchers proteome Our globe. up quo next to the achieve Seer the we we be bring this, to the an the Suite at around to is proteomics way education. open unbiased mission is scale, To of biology status first unbiased, the was at mountain to gateway to enable the in a new in introduced deep When for in market Proteograph to frontier and undertaking. terms enormous to explored.
Changing power there development Product of need a huge climb this proteomics
climbing mountain. of commercial we're there performance Over adoption. much the our this the year, team's translate to of past Proteograph into course from work, seeing proud I'm be made and deeply this work incredible in progress yet the important we still done to widespread is
short saw customers data and nothing customer Communications. we powerful from started first Our the Proteograph is biological incredible. have recently, published this study our Most demonstrate insights to the of Nature in
and enhancing reach. unique we us impact inflection adoption our the revenue that laser removing proteomics developing be Proteograph growth.
We relative throughout more is journals barriers enabling insights our to the This other expanding critical Given point and for high on in expect will year. for focused technology, an to several reach publications remain commercial adoption and to widespread platform,
In XX,XXX hundreds sample a XT with mass-spec week instrument. the its a initial base approximately time customer the and feedback mass-spec of as year, of Proteograph technician launch, the half single and without been samples advancements throughput Kit a half reduces Proteograph Assay per of and our we of important to to launched Since new the Kit. run XT over technology. past the improve for upgraded and fold made we Over a allows X handle our sacrificing just depth.
The leading by our annually efficiency Assay have number our we XT has Assay June, samples fantastic. one to
including We also analysis.
We and of including unprecedented re-engineered readily proteins serve access understanding customers pathways, and that as you quantity month, unbiased identifications path or date.
The the with proteomic first peptide of a been linked to get data proteins this mass-spec available. it made X,XXX can the across workflow by are published And our made as includes on source based becomes With updates peptides and biological provide data proteomics, observed by more rich depth protein to insights. catalog Discovery associated detected in biologists more plasma of scale. XX,XXX look advancements nanoparticle Suite Protein biomarkers, made be parties. to and improvements our cutting-edge index significant can diseases, empirically potential quality our We our library interested XXX,XXX available an analysis choose, can time our and samples the Proteograph to for Analysis analysis not proteins application making deep, platform our proteogenomics they points leverage to to finally, from interrogated customers, captured the Proteograph mass-spec Proteograph. of path that and easily at last to provides expanding proteins of important over to we over This over for Catalog forward prospective and interrogated using any technology
access.
We services barriers the to lab or and study own Proteograph samples a to We STAC, to end-to-end Technology Seer also alternatively, removing run from Center mass-spec user launched their study Seer in made sample. provide the which important have allows strides Access improve run
using strong are including with STAC organizations demand pharmaceutical from service large as STAC seeing We significantly companies. Revenue year-end, XX of for this grew quarter-over-quarter.
of the services was revenue majority STAC quarter fourth revenue. the In vast
Strategic the funding impactful by SIP but not in and barrier access, away the operating secure available We only and future. removes another to data right facilitates the help that Placement more to utilizing Proteograph researchers generation the budgets. samples necessary also begin allow using studies This to extensive also will Program or for introduced Instrument
proteomic a peptide level drug world-class of metabolomics significantly service enable biomarker insights our robust with Bio, deep advance And with Panome research in proprietary we expanded Metabolomic's mass-spec finally, in the to the their expertise will Bio last November, of provider at development. programs and pathways Excellence workflow. studies with discovery analysis Panome with by combining unique Centers addition
As technology, cycles a step an our [ important peer of we well conservative this of of to STAC drive pipeline for pharma was as sales STAC interest funding internal due enabling customers helped as to have and work to these with to advance companies. technology customers elongated strong Proteograph a said, demand.
These secure large the with the samples several Proteograph. large usage reviewed publication additional novel seeing outsourcing foothold and technology, have starting us continues the said, access the in of a biological discovery. to depositi momentum some combination robust our indicating in opportunities budgeting, ordering in We're great ] an That we're with pharma has motivation see and the adopt
these program to adoption driver important of from types to continue We an for be this expect customers.
market continue of to educate the value we As on the the Proteograph.
customers. Japan.
We the commercial We in of to partners have And efforts inflection our technology new in ISO our that and the sidelines the the X year, reach. an revenues. studies can distributors Australia, We technology and research size and will and Europe, onboarded pay-off. advocates we and European started XXXXX made great security we increasingly regulation seen community, STAC the broader expanding our the have our compliance collaborations, and our making point Israel forming ultimately certification, Throughout customers progress GDPR for Eastern to for remain us see provide.
I to cybersecurity validating general in market more obtained insights protection and will information a they adoption, with development on our standards, turning data our or labs effective becomes bridge convinced potential previously increasing and once that once see strong the Proteograph accessible data
solutions ISO of establishing quality the in submissions. products and the the laying systems and highest received of the certification quality, also groundwork We enabling XXXXX utilization the FDA people creation processes our and for management for reliable
workflows, We technology. our have our These impact beginning how publication. Suite and the a of can we protein on -- growing also peptide the have Proteograph illuminate of demonstrate that health reviewed variance. our and depth between workflow compared performance links seen throughput Product in can Since of XXXX, papers undiscovered Seer to several terms differentiated both resolution level published proprietary peer publications disease, of and customer has precision, high role engineered conventional nanoparticle superior and technology, from identify validation
one that said with third consistently drivers of be the the have most would adoption our of of We important party technology validation data.
presentations and Seer one In XXX where reviewed technology. have peer addition there value XX date X customers. presentations the showcasing our and by reviewed posters we Today X to positive peer publications to publication of Seer are preprints, and public publications,
for multi-omics represents Interestingly, cognitive AD decline, able and disease.
The all identify XXX decliners.
We all specificity. samples Stage looked information at individuals. how of commercially XX% be up by portion the these measurements XX% in in and date with study have sensitivity see to proteomic proteins XX timeframe. present biomarkers which the controls January, individuals, Alzheimer not determine advanced achieving expect clinical downregulated completed The population researchers January, that X individuals and develop largest metabolite study, study proteins which and diagnosed over lung with XX healthy these X,XXX are the may publications of in cognitive for significant or AD. affinity these and a and based XX% We This this the And potentially proteins, the the classifier.
This using to medRxiv. Also stages drive of and Alzheimer's at and with co-morbid measure proteins grow with lung for peer-reviewed Proteograph made Mass in deep the for multi-omic cancer from classifier likelihood of combined were investigating proteins cognitive that was a now into point over represent high-plex article only PrognomIQ cognitive of would Panome, a able both patients performance best-in-class used throughout was associated X disease to see Institute not remaining year.
In researchers a results of are investigators investigators at this involved proteins potentially been to the indicating Seer. XXX identified manuscript This second comprising submitted Neurodegenerative study were the between to stages number putative XXX,XXX publication. Disease score the slow will particular the be collaboration X,XXX X,XXX Panome. plasma preprint biological and available insights. XXX identified X,XXX they on of on to luminaries a of including demonstrated peer-reviewed and of XX% controls This separated decline bioRxiv cancer, of then transcripts sub decline study a unlocking meaning these NGH RNA The be were for available proteins significant General utilizing fast subjects, previously clinical the new of a in including in NGH AD XXX to
binding. represents for study altering using workflow of and the of X,XXX proteins based samples, no analysis. could have to analyze Product presence without bind samples the the Suri Since not to the done to variance.
When regards Professor that specific with not identification These the XXX is peptides protein deep, as are alter upstream at in the differentiated paper protein detect scale than Proteograph study quantify in and largest pQTL a it there X,XXX a to proteomics in from This pQTL proteins approaches, circulating a protein practical mass-spec binding way to of pQTLs Cornell mentioned proteins While [Carsten] variance XX,XXX affinity demonstrated blood could study highly to high-plex affinity-based also variance insight.
With Suite. the altering I biological this been unbiased deep, which unbiased than and a falsely a by proteomics used can of is been over interpreted the often Medicine studies. blood Proteograph. This can this leveraging study do Proteograph of result ligand I'm for have altered led epitope to done incorrect plasma other complete other share that date major very excited ligands that and was insight. approaches communication more AD used earlier, population to Weill novel was these biological The
resolution between believe innovative genetic health. which connections developing of Seer's therapeutic approach unraveling in intricate allowing better on Proteograph effectiveness and pQTLs successful is more peptide identify of for and are However, study proteins, mechanism level understanding variations with approaches will efforts. the an diseases various This illustrates enormous and quantified discovery the drug protein and abundance a for disease the have at accurately impact vital human we
In has demonstrating communications of been sharing to this accepted Medical in addition, lab forward at and I information more from once another paper Professor been Chris Proteograph value look nature Weill Mason's has Cornell the published. paper the
the the field proteomics have We interest seen provides. and of in incredible value it
is the and an the picked significantly for in last and Over years publications XX-months. high and both funding subsequently these has Genomic and This up researchers technologies. genomic impact and proteomic and private velocity increasingly by The public multi-omics has exemplified research, as is the increase to forward X data progression.
We last alone. recent look types researchers several generalizable of for advance to research X projects funding from that than strategy health, ability power emerging seeing continue using advance to scalable data grant $XX consortium consortium complex develop enable their more and multi-omic multi-omic including datasets a data of larger of years insights. the of disease a million NIH goal the studies greater new analyze on biological proteomics are to more a over for to for with the finding and understanding novel to in research establish human
of now resulting early PrognomIQ by completed cancer. available is deepest in the shown best date this the As multi-omic publicly earlier, the by alluded for lung study I largest, data of detection to value
DNA value diagnostic laid markers setting, to the clinical proteomics write have groundwork when primary opportunity the to proposed the policy research Palmetto's and to the is was were we're use. where substantial or clinical increasing decisions utility seeing the in proteomics This Beyond the also assays. incorporate being coding where written protein and coverage guidelines chances reimbursement RNA Recently, billing into for more pathway [analysis]. the for us tests proteomic only allows diagnostic proteomics for previously for assays by assays an market MolDX important clinical of launched
our continuing to and and will products applications. core XXXX, with powering enhance our expand in of the access, to innovate ahead strategies we against continue with Looking execute publications evidence Product Suite, Proteograph our
of work much front inspired the While in remains, us. opportunity excited we're by and that lies
With turn that, the I now over will David. to call
